Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To determine whether or not recently reported imbalances in putative immunoregulatory subsets of T-cells are related to impaired B-cell function in patients with multiple myeloma, we enumerated the level of T-lymphocyte subsets in and the pokeweed mitogen induced B-cell differentiation responses of blood mononuclear cells obtained from 13 patients. T-cell subsets were enumerated with the monoclonal antibodies OKT3 (peripheral T cells), OKT4 (helper/inducer cells) and OKT8 (suppressor/cytotoxic cells) using the Ortho Spectrum III fluorescence analyzer. B-cell differentiation was assessed with a reverse hemolytic plaque assay to enumerate immunoglobulin secreting cells in pokeweed mitogen stimulated cultures. Compared to controls, patients showed reduced percentages of OKT4 cells, increased percentages of OKT8 cells, and reduced OKT4/OKT8 ratios. Pokeweed mitogen induced responses were heterogeneous, but markedly depressed in 5/13 patients (hyporesponders). The percentages of OKT4 and OKT8 lymphocytes and OKT4/OKT8 ratios were similar in PWM responders and hyporesponders. Furthermore, there was no correlation between the ratio and the magnitude of the PWM response in individual patients. The data suggest that imbalances in putative immunoregulatory subsets of T cells, although common in multiple myeloma, are not likely a primary cause of impaired in vitro polyclonal B cell responses seen in this disease.
 ...
PMID:Analysis of the relationship between T cell subsets and in vitro B cell responses in multiple myeloma. 387 70

C-type particles produced by a tissue culture-adapted BALB/c myeloma were characterized. It was determined that although the particles were morphologically and antigenically similar to murine leukemia and sarcoma virus, the size of their RNA was different, they lacked RNA-dependent DNA polymerase, they were unstable in NET buffer, sucrose and citrate but were stable in glycerol and Earle balanced salt solution, and they behaved differently from oncornaviruses when treated with ether and detergent.
 ...
PMID:Characterization of C-type particles produced by a tissue culture-adapted murine myeloma. 412 86

Light chain isotype suppression in multiple myeloma has been reported in the plasma cells of the lamina propria of the gut (Leonard et al, 1979). In this paper we present further evidence of systemic suppression of the light chain isotype of the paraprotein expressed on normal peripheral blood lymphocytes in myeloma. Twenty patients with myeloma in plateau phase were monitored over 6 months for the expression of either kappa or lambda light chains on the surface of peripheral blood lymphocytes using monoclonal antibodies. The surface markers were analysed on an Ortho Spectrum III flow cytometer. Results of these studies indicate a selective suppression of the cells expressing the light chain isotype of the paraprotein in stable myeloma. Thus, in kappa myeloma there is a low kappa/lambda ratio and in lambda myeloma there is a high kappa/lambda ratio, and this suppression is lost with progressive disease.
 ...
PMID:Light chain isotype associated suppression of surface immunoglobulin expression on peripheral blood lymphocytes in myeloma during plateau phase. 643 32

Recently, high-dose chemo- and radiotherapy for newly diagnosed young patients with multiple myeloma has been established in member centers of the Nordic Myeloma Study Group (NMSG). The treatment includes supportive use of autologous hematopoietic blood progenitors harvested by leukapheresis. Safe and adequate hematopoietic support with minimal toxicity requires optimization of the number and quality of harvested progenitors. We have therefore established a workshop consisting of the 11 laboratories within the NMSG with the aim of developing recommendations for enumeration of CD34-positive cells. In this first workshop report, we discuss technical variables affecting the enumeration of progenitors harvested by leukapheresis and make specific recommendations. The products are analyzed within 4 h following erythrocyte lysis using the Ortho lysing solution for 8-10 minutes. A sample containing 0.5-1.0 x 10(6) nucleated cells is incubated with the test or control antibody (anti-CD34 = HPCA-2PE and Ms IgG1PE from Becton Dickinson) at dilutions of 1:10 to 1:40 in a final volume of 1 ml. The samples are incubated 15 minutes at ambient temperature, washed two to three times, and fixed with 1% paraformaldehyde (150 microliters/pellet) for a minimum of 10 minutes. Flow cytometric analysis is performed on 50,000 cellular events with debris eliminated. The estimation of CD34-positive cells can be performed on an FL2-side-scatter plot after marking of a positive population containing > 50 events. Using quadrant statistics, this population can be identified in the upper left quadrant, among cells with the side-scatter profile of small lymphocytic cells.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Report from a Nordic workshop on CD34+ cell analysis: technical recommendations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. Nordic Myeloma Study Group Laboratories. 753 62

The AA. report the case of a 68-year-old man, treated in their ENT-Department, presenting with amyloid accumulations in the larynx in the context of systemic amyloidosis associated to a multiple myeloma. Review of diagnostic methods in order to identify the lesion and the general malady as well. Approach to the adequate treatment.
 ...
PMID:[Laryngeal amyloidosis and multiple myeloma: a case report]. 899 97

This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of bortezomib for the treatment of multiple myeloma patients at first relapse and beyond, in accordance with the licensed indication, based upon the evidence submission from Ortho Biotech to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The outcomes stated in the manufacturer's definition of the decision problem were time to disease progression, response rate, survival and quality of life. The literature searches for clinical and cost-effectiveness studies were adequate and the one randomised controlled trial (RCT) included was of reasonable quality. Results from the RCT suggest that bortezomib increases survival and time to disease progression compared with high-dose dexamethasone (HDD) in multiple myeloma patients who have had a relapse after one to three treatments. Cost-effectiveness analysis based on the same trial and an observational study was reasonable and gave an estimated cost per life-year gained of 30,750 pounds, which ranged from 27,957 pounds to 36,747 pounds on sensitivity analysis. An attempt was made to replicate the results of the manufacturer's model and to compare the results to the Kaplan-Meier survival curve presented in the manufacturer's submission. In addition, a one-way sensitivity analysis and a probabilistic sensitivity analysis were undertaken, as well as additional scenario analyses. Based on these analyses the ERG suggests that the cost-effectiveness results presented in the manufacturer's submission may underestimate the cost per life-year gained for bortezomib therapy (versus high-dose dexamethasone) when potential UK practice and scenarios are considered. The guidance issued by NICE in June 2006 as a result of the STA states that bortezomib monotherapy for the treatment of relapsed multiple myeloma is clinically effective compared with HDD but has not been shown to be cost-effective and is not recommended for the treatment of progressive multiple myeloma in patients who have received at least one previous therapy and who have undergone, or are unsuitable for, bone marrow transplantation.
 ...
PMID:Bortezomib for the treatment of multiple myeloma patients. 1956 11

A 76-year-old patient in otherwise good health presented with a 2-year history of bilateral painless submandibular swelling and macroglossia. A standard ENT examination revealed no additional symptoms. Tongue biopsy led to the diagnosis of amyloidosis, serum immunofixation identified AL amyloidosis and a kappa light chain gammopathy resulting from multiple myeloma as the underlying cause.
 ...
PMID:[A tongue biopsy led to the diagnosis]. 2235 76

Extramedullary plasmacytomas (ESPs) are rare forms of plasma cell dyscrasias and usually are seen in the upper aerodigestive tract. ESPs with anaplastic features are extremely rare, and no treatment guidelines exist. We present a 75-year-old gentleman presented with left nasal blockage, and on examination, a polypoid left nasal mass was seen. He was, then, referred to ENT after a CT scan revealed a mass in the left nasopharynx for a biopsy. The preliminary reports suggested a high-grade lymphoma; however, after further testing, it was revealed to be an anaplastic plasma cell neoplasm. PET scan, bone marrow biopsy, serum and urine protein electropheresis, serum immunofixation and light chains were all unremarkable for systemic disease. Differential diagnosis included plasmablastic lymphoma, NK/T cell lymphoma-nasal type, and squamous cell cancers of the head and neck. He was treated with radiation alone given his comorbidities. Given there are no treatment guidelines, we would like to highlight this rare case and discuss different potential management options such as radiation, chemotherapy, surgery, or a combination of different modalities.
 ...
PMID:Extramedullary Solitary Plasmacytoma with Anaplastic Features of the Nasopharynx. 3277 47